In addition to provide the evidence for the existence of a pathogenetic IL-6/IDO1 axis in obesity, our data suggested that IL-6 blockade by TCZ may represent a promising therapeutic option for obese patients. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.